2023 U.S. Industry Statistics & Market Forecast - Pharmaceutical Preparation Manufacturing

Published: June 2023

Industry Insights

The Pharmaceutical Preparation Manufacturing industry is experiencing several key trends affecting its operations. One of the key trends is the growing demand for personalized medicine. Personalized medicine involves the customization of medical treatments for individual patients based on their genomic makeup, lifestyle, and other factors. This trend is driving the development of new treatments and therapies that are targeted to specific populations.

Another trend affecting the industry is the shift towards biologics. Biologics are drugs made from living organisms and are highly effective in targeting specific diseases, such as cancer and autoimmune disorders. As a result, many pharmaceutical companies are investing in the development and manufacturing of biologics.

The increasing use of digital technologies in healthcare is also impacting the Pharmaceutical Preparation Manufacturing industry. The use of digital technologies such as telemedicine, electronic health records, and remote patient monitoring is becoming more prevalent, which is driving the demand for drugs that can be used in conjunction with these technologies.

The industry is also facing pressure to reduce costs and increase efficiency. As a result, many pharmaceutical companies are implementing lean manufacturing practices and outsourcing non-core activities to third-party contractors.

Finally, there is an increasing focus on sustainability and environmentally friendly practices in the Pharmaceutical Preparation Manufacturing industry. Many companies are investing in renewable energy sources and reducing their carbon footprint to meet the growing demand for sustainable products.

Product & Services Breakdown

Research products and services in the Pharmaceutical Preparation Manufacturing industry generating sales. Note that products are broken into categories with different levels of classification.

Product Description	Sales ($ millions)	Percent of Total Sales
Industry Total
Medicinal And Botanical Manufacturing
Synthetic Organic Medicinal Chemicals (All Uses), Medicinal And Botanical Drugs, Chemicals, And Products, In Bulk, Alkaloid Drug
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations, Acting On The Central Nervous System And The Sense Organs, For Human Use
Pharmaceutical Preparations, Acting On The Cardiovascular System, For Human Use
Pharmaceutical Preparations, Acting On The Respiratory System, For Human Use
Pharmaceutical Preparations, Acting On Skin, For Human Use
Pharmaceutical Preparations, Vitamin, Nutrient, And Hematinic Preparations, For Human Use
Pharmaceutical Preparations, Affecting Parasitic And Infective Diseases, For Human Use (Excluding Diagnostics)
Pharmaceutical Preparation Manufacturing, Not Categorized, Total
Biological Product (Except Diagnostic) Manufacturing
Other Biologics, Excluding Diagnostic, For Human Use
Toilet Preparation Manufacturing
Creams, Lotions And Oils, Excluding Shaving, Hair, And Deodorant
Total Miscellaneous Receipts
Resales - Sales Of Products Bought And Sold Without Further Manufacture, Processing, Or Assembly
Contract Work - Receipts For Work Done For Others On Their Materials
Miscellaneous Receipts, Including Receipts For Repair Work, Sales Of Scrap And Refuse.

U.S. Geographic Distribution: Revenue Statistics by State

Market Size by State ($ millions) indicates how the industry's competition is distributed throughout the country. State-level information can identify areas with higher and lower industry market share than average.

Income Statement (Average Financial Metrics)

Financial metrics provide a snapshot view of a benchmark "average" company. Key business metrics show revenue and operating costs. The data collected covers both public and private companies.

	Industry Average	Percent of Sales (Industry Benchmark)
Total Revenue	Order at top of page
Operating Revenue
Cost of Goods Sold
Gross Profit
Operating Expenses
Pension, profit sharing plans, stock, annuity
Repairs
Rent paid on business property
Charitable Contributions
Depletion
Domestic production activities deduction
Advertising
Compensation of officers
Salaries and wages
Employee benefit programs
Taxes and Licenses
Bad Debts
Depreciation
Amortization
Other Operating Expenses
Total Operating Expenses
Operating Income
Non-Operating Income
EBIT (Earnings Before Interest and Taxes)
Interest Expense
Earnings Before Taxes
Income Tax
Net Profit Net Income

Source: AnythingResearch Analysis of U.S. federal statistics

Compensation & Salary Surveys for Employees

Compensation statistics provides an accurate assessment of industry-specific jobs and national salary averages. This information can be used to identify which positions are most common, and high, low, and average annual wages.

Title	Percent of Workforce	Bottom Quartile	Average (Median) Salary	Upper Quartile
Management Occupations	12%	Order at top of page
Chief Executives	0%
General and Operations Managers	2%
Operations Specialties Managers	5%
Business and Financial Operations Occupations	8%
Business Operations Specialists	7%
Architecture and Engineering Occupations	5%
Life, Physical, and Social Science Occupations	14%
Life Scientists	5%
Office and Administrative Support Occupations	8%
Production Occupations	34%
Other Production Occupations	29%
Chemical Processing Machine Setters, Operators, and Tenders	9%
Chemical Equipment Operators and Tenders	8%
Packaging and Filling Machine Operators and Tenders	10%
Packaging and Filling Machine Operators and Tenders	10%
Transportation and Material Moving Occupations	5%

Source: Bureau of Labor Statistics

Pharmaceutical Preparation Manufacturing Competitor Landscape & Key Companies [PREMIUM]

The most influential companies in the Pharmaceutical Preparation Manufacturing industry and adjacent industries either have large market share or are developing new business models and methods that could disrupt the status quo. We look at leading and emerging companies in the Pharmaceutical Preparation Manufacturing industry and adjacent sectors:

Market Leaders: Direct Competitors Companies with the largest market share, focused in this industry	Market leaders: Diversified Competitors Largest companies that have diversified operations in this and other industries
Innovators: Direct Competitors Innovative, Emerging, and Disruptive Companies that may influence the future direction of the industry.	Innovators: Diversified Competitors Innovators and Disruptors in adjacent industries that may also affect the Pharmaceutical Preparation Manufacturing industry.

Executive Briefings

  Competition in the pharmaceutical and biotechnology industries is intense. We face competition from a variety of companies focused on developing inflammatory, oncology and CV disease diagnostic imaging agents and other diagnostic modalities. We compete with large pharmaceutical and other specialized biotechnology companies. We also face competition from universities and other non-profit research organizations. Many emerging medical product companies have corporate partnership arrangements with large, established companies to support the research, development, and commercialization of products that may be competitive with our products. In addition, a number of large established companies are developing proprietary technologies or have enhanced their capabilities by entering into arrangements with or acquiring companies with technologies applicable to the detection or treatment of cancer and other diseases targeted by our product candidates. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biotechnology companies. Many of these competitors have products that have been approved or are in development and operate large, well-funded research and development programs. Many of our existing or potential competitors have substantially greater financial, research and development, regulatory, marketing, and production resources than we have. Other companies may develop and introduce products and processes competitive with or superior to ours.   We expect to encounter significant competition for our pharmaceutical products. Companies that complete clinical trials, obtain required regulatory approvals and commence commercial sales of their products before us may achieve a significant competitive advantage if their products work through a similar mechanism as our products and if the approved indications are similar. A number of biotechnology and pharmaceutical companies are developing new products for the treatment of the same diseases being targeted by us. In some instances, such products have already entered late-stage clinical trials or received FDA approval and may be marketed for some period prior to the approval of our products.   We believe that our ability to compete successfully will be based on our ability to create and maintain scientifically advanced “best-in-class” technology, develop proprietary products, attract and retain scientific personnel, obtain patent or other protection for our products, obtain required regulatory approvals and manufacture and successfully market our products, either alone or through third parties. We expect that competition among products cleared for marketing will be based on, among other things, product efficacy, safety, reliability, availability, price, and patent position. See Item 1A - “Risk Factors.”   Tc99m Tilmanocept Competition – Currently Approved Indications   Some surgeons who practice the lymphatic mapping procedure for which Tc99m tilmanocept is intended currently use other radiopharmaceuticals such as a sulfur colloid or other colloidal compounds. In the EU and certain Pacific Rim markets, there are colloidal-based compounds with various levels of approved labeling for use in lymphatic mapping, although a number of countries still employ products used “off-label.”   Rheumatoid Arthritis Competition   Currently, no single test is available to diagnose and monitor RA. Many of these drugs are produced and sold by large pharmaceutical companies, including AbbVie, Amgen, Bristol Meyers Squibb, Johnson Navidea Biopharmaceuticals

Government Contracts

In 2022, the federal government spent a total of $28,535,706,074 on Pharmaceutical Preparation Manufacturing. It has awarded 8390 contracts to 613 companies, with an average value of $46,550,907 per company.   

Most Recent Contracts	Date	Total Award Amount